Showing 2351-2360 of 3315 results for "".
- World’s Leading Eye Physicians and Surgeons Gather in San Francisco to Inspire the Future of Eye Carehttps://modernod.com/news/worlds-leading-eye-physicians-and-surgeons-gather-in-san-francisco-to-inspire-the-future-of-eye-care/2476986/More than 25,000 are expected to attend the American Academy of Ophthalmology’s 123rd annual meeting, AAO 2019, from Oct. 12-15 at the Moscone Center in San Francisco. The 4-day meeting offers opportunities to hear from the greatest minds in medical and surgical eye care discuss the la
- Study Reports High Sensitivity in Diabetic Retinopathy Screening Using Smartphones and Automated-AI in Primary-Carehttps://modernod.com/news/study-reports-high-sensitivity-in-diabetic-retinopathy-screening-using-smartphones-and-automated-ai-in-primary-care/2476982/Nearly 50% of patients with diabetes fail to get an annual eye examination done even in the US and Europe. In many countries, less than 10% of patients referred to ophthalmologists by their primary-care physicians actually complete a dilated retinal examination. Technology can play a role in empo
- Bausch + Lomb Enters Licensing Agreement With Intraocular Lens Design Group Tatvum Researchhttps://modernod.com/news/bausch-lomb-enters-licensing-agreement-with-intraocular-lens-design-group-tatvum-research/2476928/Bausch + Lomb announced that it has entered into a licensing agreement with Tatvum Research, a company focused on IOL development and design. Financial terms of the deal were not disclosed. The agreement provides Bausch + Lomb with worldwide commercial rights to new IOL designs for
- Konan Medical’s EyeKinetix Pupillograph is Now Available in the United Stateshttps://modernod.com/news/konan-medicals-eyekinetix-pupillograph-is-now-available-in-the-united-states/2476902/Konan Medical announced that EyeKinetix is FDA listed and now available for sale in the United States. EyeKinetix is Konan’s 2nd generation pupillograph, which is smaller, faster, easier to use and less expensive than its predecessor, RAPDx, a device that brought key pupillary testin
- Oyster Point Pharma Expands Executive Leadership Teamhttps://modernod.com/news/oyster-point-pharma-expands-executive-leadership-team/2476896/Oyster Point Pharma announced the appointment of Dan Lochner, MBA, as its Chief Financial Officer, and John Snisarenko, MBA, as Chief Commercial Officer. Mr. Lochner joins Oyster Point Pharma after spending nearly 15 years, most recently as a Managing Director, at Goldman Sachs asset mana
- Oculis Announces Appointment of Leading Ophthalmology Specialists to Scientific Advisory Boardhttps://modernod.com/news/oculis-announces-appointment-of-leading-ophthalmology-specialists-to-scientific-advisory-board/2476888/Oculis SA announced the appointments of Eric Donnenfeld, MD, and Pr. Ramin Tadayoni, MD, PhD, to its Scientific Advisory Board (SAB). “I am pleased to welcome Eric and Ramin to our SAB and look forward to their contributions as we focus on our objective of developing topical medicines that
- OD-OS to Showcase Navilas Navigated Retinal Laser Therapy at EURETINAhttps://modernod.com/news/od-os-to-showcase-navilas-navigated-retinal-laser-therapy-at-euretina/2476852/OD-OS will share clinical experiences with the Navilas 577s digital treatment platform this week at the EURETINA Congress in Paris. Navigated retinal laser therapy with the Navilas 577s allows for panretinal photocoagulation with uniform spot distribution, which is faster and less painful for pat
- Sight Sciences Raises $56M to Lead the Development of MIGS Market and Procedure-Based Dry Eye Markethttps://modernod.com/news/sight-sciences-raises-56m-to-lead-the-development-of-migs-market-and-procedure-based-dry-eye-market/2476848/Sight Sciences announced the closing of $31 million in Series D Preferred Stock financing. MidCap Financial and Sight Sciences entered into a $25 million debt facility earlier in 2019. The $56 million
- AcuFocus Completes Study Enrollment for U.S. IDE Clinical Trial of IC-8 Lenshttps://modernod.com/news/acufocus-completes-study-enrollment-for-u-s-ide-clinical-trial-of-ic-8-lens/2476806/AcuFocus announced that it has completed enrollment in its pivotal US investigational device exemption (IDE) study of the company’s IC-8 small aperture IOL. FDA granted approval of the company’s IDE on November 21, 2018, and the Investigational Review Board approved the study just 5
- Rare Complication of Eye Surgery Can Kill in a Minutehttps://modernod.com/news/rare-complication-of-eye-surgery-can-kill-in-a-minute/2476790/Ocular venous air embolism, a very rare complication of vitrectomy, is almost always fatal, yet some retina specialists have not heard of it, according to a Medscape report. The complication can kill in less than a minute, said Rob